Log In Sign up
The largest database of trusted experimental protocols

D luciferin k salt bioluminescent substrate

Manufactured by PerkinElmer
Visit Supplier
Sourced in United States

D-Luciferin K+ Salt Bioluminescent Substrate is a chemical compound used in bioluminescence assays. It is the sodium salt of D-luciferin, a naturally occurring substrate for the luciferase enzyme. The D-Luciferin K+ Salt provides a stable and water-soluble source of D-luciferin for use in various in vitro and in vivo bioluminescence-based applications.

Automatically generated - may contain errors

Lab products found in correlation

Igfbp2, by R&D Systems (1 mentions) Igf 1, by R&D Systems (1 mentions) Synergy h1 hybrid reader, by Agilent Technologies (1 mentions)

2 protocols using d luciferin k salt bioluminescent substrate

1

Evaluating IGFBP2 Effects on Multiple Myeloma Cell Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols
The BM-dependent MM cell lines, M, D and I were established in our laboratory as previously described (Li et al, 2007 (link)). To study the effects of IGFBP2 on MM cell growth, the three luciferase-expressing BM-dependent MM cell lines were cultured in serum-free αMEM for 48 h in the presence of IGF1 (40 ng/ml) and/or IGFBP2 (5 μg/ml) (R&D Systems, Minneapolis, MN, USA). After 48 h, D-Luciferin K+ Salt Bioluminescent Substrate (PerkinElmer, American Fork, UT, USA) was added to each well (1.5 mg/ml), and the bioluminescence was measured at 175 nm with a Synergy H1 hybrid reader (BioTek, Winooski, VT, USA) as described (Li et al, 2007 (link)).
Mehdi S.J., Johnson S.K., Epstein J., Zangari M., Qu P., Hoering A., van Rhee F., Schinke C., Thanendrarajan S., Barlogie B., Davies F.E., Morgan G.J, & Yaccoby S. (2018). Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. British journal of haematology, 184(4), 578-593.
+ Open protocol
+ Expand
2

Bioluminescent Tumor Imaging in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
A total of 4434 tumor-bearing mice (3 mice/group) were treated with PLX4720 and/or HSV-Fluc as described above. One day following the last intratumoral virus injection (day 8), mice were injected with 75 mg/kg D-Luciferin - K+Salt Bioluminescent Substrate (Perkin Elmer) and imaged 5 min later using The IVIS Spectrum in vivo imaging system (Perkin Elmer).
Bozhanova G., Hassan J., Appleton L., Jennings V., Foo S., McLaughlin M., Chan Wah Hak C.M., Patin E.C., Crespo-Rodriguez E., Baker G., Armstrong E., Chiu M., Pandha H., Samson A., Roulstone V., Kyula J., Vile R., Errington-Mais F., Pedersen M., Harrington K., Ono M, & Melcher A. (2022). CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. Journal for Immunotherapy of Cancer, 10(3), e004410.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!